Background: In atopic eczema (AE), skin colonization with Staphylococcus aureus plays a possible role in the pathophysiology of the disease. Methods: Thirty-eight patients with AE were screened for their cutaneous colonization with S. aureus. The antibacterial and clinical efficacy of topical therapy with the antiseptic dye gentian violet, a potent glucocorticosteroid or a tar solution (liquor carbonis detergens) was evaluated in vivo in 21 patients with a density of >104 CFU/cm2 and in vitro. Skin sites were treated twice daily for 4 days with the active drug or a corresponding control. Quantification of S. aureus was done daily during therapy as well as 3 days thereafter. The severity of the lesions was rated by a regional SCORAD. Results: In gentian-violet-treated skin, bacterial density decreased significantly in lesional (p < 0.001) and unaffected skin (p < 0.001). Bacterial densities did not decrease during therapy with glucocorticosteroid or liquor carbonis detergens but dropped afterwards. All therapeutics reduced the severity score, reduction being greatest for the glucocorticosteroid and lowest for liquor carbonis detergens. In vitro, a high antibactericidal efficacy was demonstrated only for gentian violet. Conclusions: Antibacterial therapy with gentian violet not only reduces S. aureus dramatically, but also reduces the severity of the eczema. Reduction of S. aureus after therapy with glucocorticosteroids and LCD seems to be secondary to improvement of the skin condition.

1.
Abeck D, Ruzicka T: Bacteria and atopic eczema: Merely association or etiologic factor? in Ruzicka T, Ring J, Przybilla B (eds): Handbook of Atopic Eczema. Heidelberg, Springer, 1991, pp 212–220.
2.
Williams REA, Gibson AG, Aitchison TC, Lever R, Mackie RM: Assessment of a contact-plate sampling technique and subsequent bacterial studies in atopic eczema. Br J Dermatol 1990;123:493–501.
3.
Ring J, Abeck D, Neuber K: Atopic eczema: Role of microorganisms on the skin surface. Allergy 1992;47:265–269.
4.
David TJ, Cambridge GC: Bacterial infection and atopic eczema. Arch Dis Child 1986;61: 20–23.
5.
Niedner R, Pfister-Wartha A: Farbstoffe in der Dermatologie. Akt Dermatol 1990;16:255– 261.
6.
European Task Force on Atopic Dermatitis: Severity scoring of atopic dermatitis: The SCORAD index. Dermatology 1993;186:23– 31.
7.
Williamson P, Kligman AM: A new method for quantitative investigation of cutaneous bacteria. J Invest Dermatol 1965;45:498–503.
8.
Brockow K, Grabenhorst P, Traupe B, Ring J, Hoppe U, Abeck D, Wolf F: A rapid impedimetric procedure for quantification of staphylococcal skin colonisation in atopic eczema. J Invest Dermatol 1998;110:668.
9.
Bible DJ, Aly R, Shinefield HR, Maibach HI, Strauss WG: Importance of the keratinized epithelial cell in bacterial adherence. J Invest Dermatol 1982;79:250–253.
10.
Bakker P, Van Doorne H, Gooskens V, Wieringa NF: Activity of gentian violet and brilliant green against some microorganisms associated with skin infections. Int J Dermatol 1992;31:210–213.
11.
Lever R, Hadley K, Downey D, Mackie R: Staphylococcal colonization in atopic dermatitis and the effect of topical mupirocin therapy. Br J Dermatol 1988;119:189–198.
12.
Ring J, Brockow K, Abeck D: The concept of patient management in atopic eczema. Allergy 1996;51:206–213.
13.
Marples RR, Rebora A, Kligman AM: Topical steroid-antibiotic combinations: Assay of use in experimentally induced human infections. Arch Dermatol 1973;108:237–240.
14.
eyden JJ, Kligman AM: The case for steroid-antibiotic combinations. Br J Dermatol 1977; 96:179–187.
15.
Gehring W, Forssmann T, Gloor M: Die keimreduzierende Wirkung von Erythromycin und Triclosan bei der atopischen Dermatitis. Akt Dermatol 1996;22:28–31.
16.
Lloyd KM: The value of neomycin in topical corticosteroid preparations. South Med J 1969; 62:94–96.
17.
Clark RF: The case for corticosteroid-antibiotic combinations. Cutis 1974;14:737–741.
18.
Wachs GN, Maibach HI: Co-operative double-blind trial of an antibiotic corticoid combination in impetiginized atopic dermatitis. Br J Dermatol 1976;95:323–328.
19.
Nilsson EJ, Henning CG, Magnusson J: Topical corticosteroids and Staphylococcus aureus in atopic dermatitis. J Am Acad Dermatol 1992; 27:29–34.
20.
Korting HC, Zienicke H, Braun-Falco O, Bork K, Milbradt R, Nolting S, Schopf E, Tronnier H: Modern topical glucocorticosteroids and anti-infectives for superinfected atopic eczema: Do prednicarbate and didecyldimethylammoniumchloride form a rational combination? Infection 1994;22:390–394.
21.
Davies CM, Fulghum DD, Taplin D: The value of neomycin in a neomycin-steroid cream. JAMA 1968;203:136–138.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.